Myeloma Biomarker - Predicting benefit and improving outcomes of high dose therapy and autologous stem cell transplantation for myeloma patients through tissue-array based classification.
| Period from: | 2009-03-01 to 2012-02-28 |
| Principal Investigators: | Dr. Douglas Stewart |
| Co-Investigators: | Nizar Bahlis, Anthony Magliocco, Adnan Mansoor, Michael Eliaswiz, Neil Chua, Raymond Lai |
| Institution: | Alberta Cancer Board |
| Department: | Tom Baker Cancer Centre |
| Partner: | Alberta Cancer Board |
| Program: | Research Project |
| Abstract: |
High dose chemotherapy and stem cell transplantation significantly improves the survival outcomes of the majority of the patients affected by multiple myeloma. However nearly one-third of these patients do not benefit from such approach and should be spared the toxicity of high-dose therapy.
Our goals are to maximize the therapeutic benefits of stem cell transplantation in multiple myeloma by designing easily applicable and reliable methods of interrogating the tumor cells, allowing us to select ahead of time the patients who would benefit from such approach.
To attain this goal we intend to use gene-array profiling as a tool for biomarkers discovery and then translate these biomarkers into a low-cost and easily reproducible tissue-array based approach. Establishing "individualized" treatment approaches by interrogating the tumor tissue will help us improve the survival of our patients and minimize the toxicity of our medical interventions.
|
| Funding Information: | |
| 2008-2009 | $18,708 |
| 2009-2010 | $224,326 |
| 2010-2011 | $224,480 |
| 2011-2012 | $203,940 |
| TOTAL | $669,454 |
|
 |
